Search Videos and More
News
U.S. News & World Report Recognizes Fox Chase Cancer Center Among Nation’s Best Hospitals for Cancer Care
U.S. News & World Report has ranked Fox Chase Cancer Center among the nation’s top hospitals for cancer care according to the publication’s 2026-27 Best Hospitals rankings.
News
It Takes a Community for a Winn Scholar to Build a Clinical Trial
“My past experiences with Teach for America in North Philadelphia were a prologue to what I am doing now,” said Austin Williams, MD, MSEd, FACS, a surgical oncologist specializing in breast cancer at Fox Chase Cancer Center and Associate Program Director of the Breast Oncology Fellowship at Fox Chase.
News
Inspiration for Patients and Peers
Meet the Fox Chase physicians and researchers bridging clinical care excellence with breakthroughs in research—bringing new ideas and new hope to peers, patients, and their families.
News
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs. Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer - Clinical Trial
This is a randomized, phase 3, multicenter trial designed to determine if induction weekly chemotherapy, when added to standard concurrent chemoradiotherapy and immunotherapy, for locally advanced cervical cancers can improve disease control and cure rate. The outcome for this study will be assessed over the first 2-3 years following completion of the therapy to which the patient is randomized.
News
From Fellowship to Faculty: Building a Fox Chase Career
Arielle Weiss, MD, Assistant Professor, Department of Surgery, and Jason Conger, MD, Assistant Professor, Department of Surgery, both in the Division of Gynecologic Oncology, came to Fox Chase Cancer Center shaped by different experiences, but ultimately each found the “right fit” in choosing a gynecologic oncology fellowship at Fox Chase and later joining its faculty.
News
From Bench to Bedside to the Block: Dr. Robert A. Winn on Extending Fox Chase's Legacy of Cancer Discovery and Bringing It to the Community
As he begins his tenure at Fox Chase Cancer Center, Dr. Robert Winn brings a national reputation in cancer leadership, discovery, and equitable access - and a vision for science that reaches farther than the clinic.
News
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
News
Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced).
News
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This is a multicenter randomized control trial evaluating novel BTK degrader (BGB-16673) versus standard of care pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had progressive disease on a prior line containing a covalent Bruton tyrosine kinase inhibitor (cBTKi). Patient are allowed but not required to have previously received venetoclax (or other BCL2 directed therapy).
News
Surgery With or Without Neoadjuvant Chemotherapy in High-Risk RetroPeritoneal Sarcoma (STRASS2)
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
News
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer (NEPTUNE)
This trial is a multi-site, single-arm, phase II trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.
News
Doximity Ask AI May Be Smart, but Trusted Answers Still Depend on Physicians Like Dr. Cohn
A longtime Doximity user, Joshua Cohn, MD, FPMRS, Associate Professor, Department of Urology, Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute provider, had relied on the company’s dialer service for years.